(Reuters) – Drug developer Zogenix Inc said on Tuesday that it would push back late-stage trials of its treatment for a rare form of epilepsy by about three months to enroll more patients. The company said it now planned to begin late-stage trials of the drug, ZX008, in the fourth quarter, and would seek to enroll 105 patients in the studies, up from 40 to 60 earlier, acting on guidance
By Andrew M. Seaman (Reuters Health) – New guidelines for prescribing cholesterol-lowering medications are efficient and cost-effective, according to two new studies. The new research, published in JAMA, examines the 2013 recommendation that people ages 40 to 75 with at least a 7.5 percent risk of having a heart attack or stroke over the next 10 years receive statin drugs. “We decide to look at this, because we felt it
By Keith Coffman CENTENNIAL, Colo. (Reuters) – Lawyers in the trial of Colorado movie massacre gunman James Holmes will make their closing arguments on Tuesday to jurors who must decide whether he is a calculating mass murderer or was legally insane when he killed 12 people. Prosecutors and the defense have been allotted two hours each to present their case by Arapahoe County District Court Judge Carlos Samour, after testimony
You and dark chocolate have a long-standing love affair.
The recall comes after the USDA received reports that a cluster of people in Minnesota and Wisconsin became sick between mid-April and late June after eating Barber products.
New research published in the American Journal of Preventative Medicine has found a consistent link between secondhand smoke and the risk of stroke. Interestingly, women are more at risk.
Chanel White, age 23, is living with a rare chronic disease that slowly hardens her skin and organs.
When I heard a mathematician had developed a formula for lasting love, the only thing I did is let out a groan.
The Dumfriesshire yard that produced over 640 winners including two at the Cheltenham festival and a Northumberland Plate for Len Lungo is set to have a new trainer’s name above the door.
Chris Froome extended his lead of the Tour de France by blowing all of his rivals away with an emphatic victory on stage 10’s summit finish in the Pyrenees.
